Dr. Reddy's Laboratories heads into its May 19 results with short sellers meaningfully more active than they were a month ago — the most notable shift in the positioning picture going into the print.
Shorts have added aggressively in the run-up. Estimated shares short jumped roughly 18% over the past week to 16.1 million, and are up about 14% from a month ago. Days to cover from the official FINRA data stand at 5.55, meaning it would take shorts the better part of a trading week to unwind at average volumes. The ORTEX short score — a composite measure of borrowing pressure — has drifted higher all week, reaching 55.1. Borrow availability has tightened in step: utilization has climbed to nearly 70%, up sharply from around 40% in early April, though still well below the 52-week peak of 90%. Cost to borrow, at 0.62%, remains modest in absolute terms, suggesting the build in short interest reflects conviction rather than forced covering pressure.
Options positioning offers a softer read on sentiment. The put/call ratio at 0.56 is actually above the 20-day average of 0.37, but the z-score of just 0.43 places the reading comfortably within normal range — not a defensive extreme. Notably, the PCR swung from above 1.1 in early May to below 0.6 by week's end, a reversal that may reflect call buying as the stock gained roughly 3% over the past week to close at $13.61. That price gain is a modest positive into the print, running about 3.7% above where it was a month ago.
The bull case rests on the stock's dividend consistency — the factor score for dividend quality ranks in the 90th percentile — and a valuation that, on a price-to-book of 2.5x and a PE of 23x, is not stretched for a generics heavyweight with meaningful US market exposure. The EV/EBITDA of roughly 14x has crept higher over the past month, suggesting the market has been willing to pay incrementally more. HSBC upgraded the ADR to Buy in June 2025, citing a target of $16.90 against the then-price of around $14 — that thesis has not yet fully played out. Bears, meanwhile, can point to the short-interest build itself as a signal that some investors see earnings risk, alongside an EPS surprise score that ranks in only the 13th percentile, suggesting the company's track record of beating estimates is weak.
Boston Partners added over 4 million shares in the most recent filing period, becoming one of the more notable buyers among international institutional names. Norges Bank also added 3.6 million shares through year-end 2025. That incremental institutional accumulation provides some demand-side support, even as the short-side pressure intensifies.
The print will test whether the pickup in short positioning is vindicated by a miss on earnings or revenue guidance — or whether it becomes the fuel for a reversal if the numbers hold up.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
